A bill to study the therapeutic effects of psilocybin and MDMA has been quietly advancing through the Texas legislature.
Introduced in February by Texas state Rep. Alex Dominguez (D), the bill would direct the Department of State Health Services and Texas Medical Board to study psilocybin, MDMA and ketamine for the treatment of post-traumatic stress disorder (PTSD) and other ailments.
The legislation places special focus on psychedelics as a tool to improve the health and quality of life of military veterans. Research would be conducted at the Baylor College of Medicine and “a military veterans hospital or a medical center that provides medical care to veterans.”
The current bill also mandates a clinical trial on psilocybin for veterans with PTSD.
The bill passed a House vote earlier this month and on Wednesday received clearance from the Senate Veteran Affairs & Border Security Committee in a 5-0 vote, reported Marijuana Moment.
The bill now heads to the Senate floor for a final vote before sending it to Gov. Greg Abbott's desk.
Photo: Texas State Capitol by by Kyle Glenn on Unsplash
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!
